Dr. Kavita Singh

Qualification               : M. Pharm., Ph.D.(Tech.), PGDPL.

Specialization             : Pharmaceutics

E mail                          : kavita.singh@nmims.edu / kspharma05@gmail.com

Phone                          : 022-42332000 (Extn- 2022)/ 9833084398.

Experience                  : 14 years (Industry: 2 years, Academics: 12 years)

She has two years of industrial experience as a Research Associate with reputed pharmaceutical organizations, including Pfizer India Pvt. Ltd. and Ipca Laboratories Pvt. Ltd. During her doctoral research, she worked as a Senior Research Fellow, CSIR on a research project sponsored by Relmada Therapeutics, USA. She has also been an active faculty member at SVKM’s NMIMS’s SPPSPTM, Mumbai since December 2014, contributing extensively to academics, translational research and institutional activities.

Interest areas:

• Nanocarrier Systems: Extensive experience in polymeric-and lipid-based nanocarriers for targeted and controlled drug delivery for various routes.
• Ophthalmic Drug Delivery: Expertise in designing and developing novel ophthalmic drug delivery systems like siRNA delivery and targeted nano-carrier development.
• Oral Drug Delivery: Expertise in colon-targeted drug delivery systems, osmotic drug delivery systems and extended-release matrix-based oral solid dosage forms. Experience in the design and evaluation of pharmacokinetic studies for pharmaceutical formulations
• Anti-Aging Research: Keen interest and expertise in exploring novel anti-aging interventions, Cellular markers and innovative delivery strategies.

• Publications – 50 (International- 45, National- 05)
• Book Chapters- 12
• Patents- 04 (03 granted, 01 Filed)
• Presentations- 25 (International- 09, National- 16)

• Government funded projects – 02
  • Completed (02)
  • Received Research grant of approx. 30 Lacs under the scheme, Core Research Grant of Science & Engineering Research Board (SERB), DST, Govt. of India for the project entitled "Development of Novel formulation for minimally invasive or non-invasive ocular delivery of Anti-VEGF macromolecule for retinoblastoma” from March 2021-2024.
  • Received Research grant of approx. 41 Lacs under the scheme, Early Career Research Award of Science & Engineering Research Board (SERB), DST, Govt. of India for the project entitled "Development and assessment of novel formulations containing therapeutic proteins and siRNA for treatment of Diabetic retinopathy” from March 2018-2021.

• Industry projects (Completed)

• In-vivo pharmacokinetic evaluation of a topical formulation; funded by Vici Health Sciences, USA. (Rs. 20 lacs) from May 2022 to April 2023.
• Development of ophthalmic suspension to cure ocular inflammation; funded by Vici Health Sciences, USA. (Rs. 17 lacs) from Oct 2021 to Dec 2022.
• Evaluation of anti-aging potential of novel Elixir formulation; funded by Nugenics Research Pvt Ltd, Mumbai, India. (Rs. 10 lacs) from Jan-Dec 2022.
• Evaluation of anti-aging potential of novel Elixir formulation; funded by Nugenics Research Pvt Ltd, Mumbai, India. (Rs. 10 lacs) from Jan 2021 to Dec 2021.
• Development of novel Anti-aging modalities; funded by Nugenics Research Pvt Ltd, Mumbai, India. (Rs. 25 lacs) from Nov 2017 to Dec 2020.
• In-vivo Pharmacokinetic Evaluation of lipidic Formulations; funded by Gattefosse India Pvt. Ltd., Mumbai, India. (Rs. 4.72 lacs) from Oct 2019 to Sep 2020.
• Pharmacokinetic Evaluation of Curcumin Formulation with Gelucire 48/16; funded by Gattefosse India Pvt. Ltd., Mumbai, India. (Rs. 4.72 lacs) from Feb 218 to Aug 2018.

• Industrial projects (On-going):
• Development and evaluation of novel composition for age-related conditions; funded by Yuvan Research Inc. (Approx. USD 2500.00) for a duration of ~18 months (2025–26).
• Bioanalytical method development and in-vivo pharmacokinetics study of developed oral formulation; funded by Shin-Etsu Chemical Co. Ltd. (Approx. Rs. 6.1 lacs) from 2025–26.
• Multiple projects on "Testing the ex-vivo permeability of given test samples”; funded by Evonik Operations GmbH. (Approx. Rs. 4.0 lacs) (2025–26).
• Two projects on "Testing the Particle size and molecular weight of given test samples”; funded by Evonik Operations GmbH. (Approx. Rs 0.78 lacs) (2025–26).
• Physicochemical characterization and in-vitro studies of Plasma fraction E5; funded by Nugenics Research Pvt. Ltd (Approx. 4.72 Lacs) for a duration of ~24 months (2024–26).

Conferences/Workshops/Seminars attended- More than 35

Academic activities

• She has guided 31 M.Pharm. students, 03 PhDs and 3 Post Ph.D. Research Associates for their research projects. Also, currently she is guiding 04 Ph.D. scholars for their doctoral research projects. 
• Kavita Singh is appointed as Technical Expert for E-content and video development for Units of Physical Pharmacy under National mission on education through information and communication (NMEICT), Consortium for Educational Communication, UGC MHRD PROJECT by Educational Multimedia Research Centre (EMMRC) as per the guidelines framed by UGC, Consortium for Educational Communication.
• Appointed as External referee for conducting Viva-Voce examinations of B. Pharm and M. Pharm. (Pharmaceutics) students from University of Mumbai and SNDT Women’s University.

 Awards

• Awarded Senior Research Fellowship for the doctoral research by Council of Scientific and Industrial Research, Govt. of India, New Delhi, India in April 2012.
• Ratan Tata scholarship, Sir Dorabji Tata Trust, Fort, Mumbai for the Year 2001-2002.
• PhD student at SPPSPTM, Ms. Shibani Supe under the guidance of Kavita Singh received BEST POSTER award for her work entitled "Optimized polyethylenimine (PEI) based lipopolyplexes for siRNA delivery, analyzed in vitro for targeting VEGF indirectly” at 6th Annual International Conference on Global Trends in IPR:Patenting and Beyond, organized by Goa – Center for Excellence in Intellectual Property [G-CEIP] held in Dec 2021. The work presented in the conference was outcome of a government funded (approx. INR 42 Lacs) research project under the scheme of Early Career Award, SERB DST, GOI received by Dr. Kavita Singh in capacity of Principal Investigator.
• Kavita Singh from SPP-SPTM NMIMS, University, Mumbai along with Team Gattefossé India participated in an event Disso Research Presentations India-2021 (DRPI 2021) and presented a research work entitled "In-vitro Dissolution Vs In-vitro Lipolysis: Which is better to predict the In-vivo performance of Lipid Formulations?”.
• Received international travel support of Rs. 2 lacs to present research work entitled - Development and Evaluation of Hydrogel Based Contact Lens of Ganciclovir for Treatment of Cytomegalovirus Retinitis, at 2017 AAPS Annual Meeting and Exposition, held in San Diego, USA from 12-11-2017 to 15-11-2017.
• Received 3rd prize for oral presentation on project entitled "Formulation and development of gabapentin–loaded lipid nanoparticle gel” in a conference on Novel Formulation Strategies, held on 12-13 April 2018 at Ramada Powai Hotel and Convention Centre, Mumbai, India.
• Obtained 4th rank in P.G. Diploma in Patent Law from NALSAR University of Law, Hyderabad, India in May 2017 with A+ grade.
• First Prize for poster presentation entitled "Investigation of In-vitro In vivo release profiles of Buprenorphine HCl loaded nanoparticles for colon targeting” at DISSO INDIA 2013, International Annual Symposium organized by Society of Pharmaceutical Dissolution Science at Mumbai, India.

Professional Memberships

• Life member of Indian Pharmaceutical Association 
• Life member of Association of Pharmaceutical Teachers of India
• Registered pharmacist in FDA Maharashtra

Recent Publications

1. Mudassir Ansari, Yogesh Kulkarni, Kavita Singh. Dissolvable microneedles assisted minimally invasive transcleral delivery of conjugated Soluplus nanomicelles targeting retina in the management of retinoblastoma. Journal of Pharmaceutical Sciences. Aug 2025;114(8):103835 (Impact factor- 3.9; Q1 journal ).
2. Vamika Khanna, Kavita Singh. MicroRNAs as promising drug delivery target to ameliorate chronic obstructive pulmonary disease using nano-carriers: A comprehensive review. Molecular and Cellular Biochemistry. Mar 2025;480(3):1431–1448 (Impact factor- 4.7; Q1 journal ).
3. Amin Haghani, et al. DNA methylation networks underlying mammalian traits. SCIENCE. Aug 2023;381(6658) (Impact factor- 56.9; Q1 journal ).
4. Haghani, A. et al. Universal DNA methylation age across mammalian tissues. NATURE AGING. 2023 Aug;3(8):1144–1166 (Impact factor- 16.6; Q1 journal).
5. Kavita Singh, Shraddha Khairnar, Akshay Sanghavi, Tanuja Yadav, Neha Gupta, Jay Arora, Harold Katcher. E5 treatment showing improved health-span and lifespan in old Sprague Dawley rats. Aging Cell. Dec 2024;23(12):e14335 (Impact factor- 8.0; Q1 journal ).
6. Shibani Supe, Archana Upadhya, Vikas Dighe, Kavita Singh. Development and characterization of modified chitosan lipopolyplex for an effective siRNA delivery. AAPS PharmSciTech. Jan 2024;25(1):13 (Impact factor- 4.0; Q1 journal ).
7. Ujwala Shinde, Abhijit De, Rutika D. Godse, Maithreyi Rathod, Rahul Thorat, Nisha Sharma, Mudassir Ansari, Kavita Singh. Efficacy evaluation of carboplatin-etoposide Co-loaded PLGA microparticles for subconjunctival chemotherapy in retinoblastoma. Journal of Drug Delivery Science and Technology. 2024 Jan;92:105333 (Impact factor- 4.9; Q1 journal ).
8. Steve Horvath, Kavita Singh, Ken Raj, Shraddha I. Khairnar, Akshay Sanghavi, Agnivesh Shrivastava, et al. Reversal of biological age in multiple rat organs by young porcine plasma fraction. GeroScience. Volume 46, pages 367–394 (2024) (Impact factor- 5.5; Q1 journal).
9. Siddhi lokhande, Yukta Bhandari, Mudassir Ansari, Shraddha Khairnar, Kavita Singh. Development and evaluation of biodegradable nanofiber insert containing hyaluronic acid for treatment of dry eye syndrome. Journal of drug delivery science and technology. 2023 Sept;87:104847 (Impact factor- 4.9; Q1 journal ).
10. Shibani Supe, Archana Upadhya, Santosh Tripathi, Vikas Dighe, Kavita Singh. Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy. Drug delivery and translational research. 2023 Jun;13(6):1675-1698 (Impact factor- 5.5; Q1 journal).